PL2606032T3 - Kompozycja i sposoby terapii glejakaep - Google Patents
Kompozycja i sposoby terapii glejakaepInfo
- Publication number
- PL2606032T3 PL2606032T3 PL11749677T PL11749677T PL2606032T3 PL 2606032 T3 PL2606032 T3 PL 2606032T3 PL 11749677 T PL11749677 T PL 11749677T PL 11749677 T PL11749677 T PL 11749677T PL 2606032 T3 PL2606032 T3 PL 2606032T3
- Authority
- PL
- Poland
- Prior art keywords
- composition
- methods
- treating glioblastomas
- glioblastomas
- treating
- Prior art date
Links
- 208000005017 glioblastoma Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C07D219/12—Amino-alkylamino radicals attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37570410P | 2010-08-20 | 2010-08-20 | |
| EP11749677.8A EP2606032B1 (en) | 2010-08-20 | 2011-08-22 | Composition and methods for treating glioblastomas |
| PCT/US2011/048594 WO2012024670A2 (en) | 2010-08-20 | 2011-08-22 | Composition and methods for treating glioblastoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2606032T3 true PL2606032T3 (pl) | 2015-07-31 |
Family
ID=44533208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11749677T PL2606032T3 (pl) | 2010-08-20 | 2011-08-22 | Kompozycja i sposoby terapii glejakaep |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9034895B2 (pl) |
| EP (1) | EP2606032B1 (pl) |
| ES (1) | ES2530629T3 (pl) |
| PL (1) | PL2606032T3 (pl) |
| WO (1) | WO2012024670A2 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2638057B1 (es) * | 2017-03-02 | 2018-10-01 | Universidad Del País Vasco / Euskal Herriko Unibertsitatea | Tratamiento de la demencia con agonistas cannabinoides |
| WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
| KR20240072339A (ko) * | 2022-11-14 | 2024-05-24 | 주식회사 힐리노엘에스 | 교모세포종의 예방, 개선 또는 치료용 화합물을 유효성분으로 포함하는 조성물 |
| CN118812442B (zh) * | 2024-06-19 | 2025-10-03 | 四川省医学科学院·四川省人民医院 | 能提升血脑屏障通透性的化合物、其制备方法及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013837A (en) | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| AU2002302248B2 (en) * | 2001-05-23 | 2008-03-06 | Merck Frosst Canada Ltd. | Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists |
| US20050009903A1 (en) | 2003-06-10 | 2005-01-13 | Martin Billy R. | CB2-selective cannabinoid analogues |
-
2011
- 2011-08-22 US US13/818,026 patent/US9034895B2/en active Active
- 2011-08-22 PL PL11749677T patent/PL2606032T3/pl unknown
- 2011-08-22 EP EP11749677.8A patent/EP2606032B1/en not_active Not-in-force
- 2011-08-22 WO PCT/US2011/048594 patent/WO2012024670A2/en not_active Ceased
- 2011-08-22 ES ES11749677T patent/ES2530629T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012024670A2 (en) | 2012-02-23 |
| EP2606032A2 (en) | 2013-06-26 |
| EP2606032B1 (en) | 2015-01-07 |
| US9034895B2 (en) | 2015-05-19 |
| ES2530629T3 (es) | 2015-03-04 |
| US20130197026A1 (en) | 2013-08-01 |
| WO2012024670A3 (en) | 2012-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253870A0 (en) | Certain amino-pyrimidines, their assemblies, and methods of using them | |
| SG2014010706A (en) | Method and composition | |
| GB201016001D0 (en) | Composition and method | |
| ZA201302625B (en) | Methods and compositions for treating hemophilia b | |
| EP2655334A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
| ZA201303423B (en) | Compositions and methods for treating myelofibrosis | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| ZA201208578B (en) | Composition,method and use | |
| IL222465A0 (en) | Certain amino-pyridazines, compositions thereof, and methods for their use | |
| SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
| GB201122195D0 (en) | Composition and method | |
| EP2590674A4 (en) | COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT | |
| IL225483A0 (en) | The compositions and methods for the treatment of neoplasia | |
| IL232648A0 (en) | Preparations and methods for treating glioma | |
| GB201003531D0 (en) | Composition and method | |
| GB201106433D0 (en) | Composition and method | |
| GB201008364D0 (en) | Composition and method | |
| EP2566478A4 (en) | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPERTENSION | |
| GB201008843D0 (en) | Method and composition | |
| PL2606032T3 (pl) | Kompozycja i sposoby terapii glejakaep | |
| GB2500357B (en) | Combination and composition for treating obesity | |
| EP2632432A4 (en) | COMPOSITION AND METHOD FOR TREATING LESIONS | |
| ZA201308683B (en) | Methods and compositions suitable for preventing and treating hyperleptinemia | |
| GB201001243D0 (en) | Composition and method | |
| GB201002240D0 (en) | Composition and method |